These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 36271032)

  • 21. Overall survival of pancreatic ductal adenocarcinoma is doubled by
    Lee JS; Lee H; Woo SM; Jang H; Jeon Y; Kim HY; Song J; Lee WJ; Hong EK; Park SJ; Han SS; Kim SY
    Theranostics; 2021; 11(7):3472-3488. PubMed ID: 33537098
    [No Abstract]   [Full Text] [Related]  

  • 22. A low amino acid environment promotes cell macropinocytosis through the YY1-FGD6 axis in Ras-mutant pancreatic ductal adenocarcinoma.
    Zhang YF; Li Q; Huang PQ; Su T; Jiang SH; Hu LP; Zhang XL; Sun Y; Pan H; Yang XM; Li J; Gai YZ; Zhu L; Yao LL; Li DX; Sun YW; Zhang ZG; Liu DJ; Zhang YL; Nie HZ
    Oncogene; 2022 Feb; 41(8):1203-1215. PubMed ID: 35082383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of Rnf43 Accelerates Kras-Mediated Neoplasia and Remodels the Tumor Immune Microenvironment in Pancreatic Adenocarcinoma.
    Hosein AN; Dangol G; Okumura T; Roszik J; Rajapakshe K; Siemann M; Zaid M; Ghosh B; Monberg M; Guerrero PA; Singhi A; Haymaker CL; Clevers H; Abou-Elkacem L; Woermann SM; Maitra A
    Gastroenterology; 2022 Apr; 162(4):1303-1318.e18. PubMed ID: 34973294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer.
    Morton JP; Timpson P; Karim SA; Ridgway RA; Athineos D; Doyle B; Jamieson NB; Oien KA; Lowy AM; Brunton VG; Frame MC; Evans TR; Sansom OJ
    Proc Natl Acad Sci U S A; 2010 Jan; 107(1):246-51. PubMed ID: 20018721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hes1 plays an essential role in Kras-driven pancreatic tumorigenesis.
    Nishikawa Y; Kodama Y; Shiokawa M; Matsumori T; Marui S; Kuriyama K; Kuwada T; Sogabe Y; Kakiuchi N; Tomono T; Mima A; Morita T; Ueda T; Tsuda M; Yamauchi Y; Sakuma Y; Ota Y; Maruno T; Uza N; Uesugi M; Kageyama R; Chiba T; Seno H
    Oncogene; 2019 May; 38(22):4283-4296. PubMed ID: 30705405
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cell of origin affects tumour development and phenotype in pancreatic ductal adenocarcinoma.
    Lee AYL; Dubois CL; Sarai K; Zarei S; Schaeffer DF; Sander M; Kopp JL
    Gut; 2019 Mar; 68(3):487-498. PubMed ID: 29363536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ANGPTL4 accelerates KRAS
    Yan HH; Jung KH; Lee JE; Son MK; Fang Z; Park JH; Kim SJ; Kim JY; Lim JH; Hong SS
    Cancer Lett; 2021 Oct; 519():185-198. PubMed ID: 34311032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dinaciclib prolongs survival in the
    Yang J; Hu S; Shangguan J; Eresen A; Li Y; Ma Q; Yaghmai V; Benson Iii AB; Zhang Z
    Am J Transl Res; 2020; 12(3):1031-1043. PubMed ID: 32269732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GNAS(R201H) and Kras(G12D) cooperate to promote murine pancreatic tumorigenesis recapitulating human intraductal papillary mucinous neoplasm.
    Taki K; Ohmuraya M; Tanji E; Komatsu H; Hashimoto D; Semba K; Araki K; Kawaguchi Y; Baba H; Furukawa T
    Oncogene; 2016 May; 35(18):2407-12. PubMed ID: 26257060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glucose metabolism during tumorigenesis in the genetic mouse model of pancreatic cancer.
    Pasquale V; Dugnani E; Liberati D; Marra P; Citro A; Canu T; Policardi M; Valla L; Esposito A; Piemonti L
    Acta Diabetol; 2019 Sep; 56(9):1013-1022. PubMed ID: 30989379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma.
    Liang C; Qin Y; Zhang B; Ji S; Shi S; Xu W; Liu J; Xiang J; Liang D; Hu Q; Ni Q; Xu J; Yu X
    Mol Cancer Res; 2017 Feb; 15(2):201-212. PubMed ID: 28108627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dichotomous role of the serine/threonine kinase MAP4K4 in pancreatic ductal adenocarcinoma onset and metastasis through control of AKT and ERK pathways.
    Juin A; Spence HJ; Machesky LM
    J Pathol; 2024 Apr; 262(4):454-466. PubMed ID: 38229581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
    Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
    Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers.
    Cheng R; Li F; Zhang M; Xia X; Wu J; Gao X; Zhou H; Zhang Z; Huang N; Yang X; Zhang Y; Shen S; Kang T; Liu Z; Xiao F; Yao H; Xu J; Yan C; Zhang N
    Cell Res; 2023 Jan; 33(1):30-45. PubMed ID: 36241718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma.
    Li JT; Yin M; Wang D; Wang J; Lei MZ; Zhang Y; Liu Y; Zhang L; Zou SW; Hu LP; Zhang ZG; Wang YP; Wen WY; Lu HJ; Chen ZJ; Su D; Lei QY
    Nat Cell Biol; 2020 Feb; 22(2):167-174. PubMed ID: 32029896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RET, a targetable driver of pancreatic adenocarcinoma.
    Amit M; Na'ara S; Fridman E; Vladovski E; Wasserman T; Milman N; Gil Z
    Int J Cancer; 2019 Jun; 144(12):3014-3022. PubMed ID: 30515799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer.
    Purohit A; Varney M; Rachagani S; Ouellette MM; Batra SK; Singh RK
    Oncotarget; 2016 Feb; 7(6):7280-96. PubMed ID: 26771140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ARID1A Maintains Differentiation of Pancreatic Ductal Cells and Inhibits Development of Pancreatic Ductal Adenocarcinoma in Mice.
    Kimura Y; Fukuda A; Ogawa S; Maruno T; Takada Y; Tsuda M; Hiramatsu Y; Araki O; Nagao M; Yoshikawa T; Ikuta K; Yoshioka T; Wang Z; Akiyama H; Wright CV; Takaori K; Uemoto S; Chiba T; Seno H
    Gastroenterology; 2018 Jul; 155(1):194-209.e2. PubMed ID: 29604291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.